Lupin (LUPIN) Stock Overview
Operates as a pharmaceutical company in India, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
LUPIN Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Lupin Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,973.60 |
| 52 Week High | ₹2,402.90 |
| 52 Week Low | ₹1,795.20 |
| Beta | 0.30 |
| 1 Month Change | 1.77% |
| 3 Month Change | -0.37% |
| 1 Year Change | -10.22% |
| 3 Year Change | 173.66% |
| 5 Year Change | 91.76% |
| Change since IPO | 24,401.55% |
Recent News & Updates
Recent updates
With EPS Growth And More, Lupin (NSE:LUPIN) Makes An Interesting Case
Aug 27
Lupin Limited Just Recorded A 12% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 08We Take A Look At Why Lupin Limited's (NSE:LUPIN) CEO Has Earned Their Pay Packet
Aug 05Lupin (NSE:LUPIN) Is Paying Out A Larger Dividend Than Last Year
Jul 17Why Investors Shouldn't Be Surprised By Lupin Limited's (NSE:LUPIN) Low P/E
Jul 12Is Lupin (NSE:LUPIN) Using Too Much Debt?
Jun 24Analysts Are Updating Their Lupin Limited (NSE:LUPIN) Estimates After Its Annual Results
May 19We Ran A Stock Scan For Earnings Growth And Lupin (NSE:LUPIN) Passed With Ease
Apr 18Investors Still Waiting For A Pull Back In Lupin Limited (NSE:LUPIN)
Mar 04Earnings Beat: Lupin Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Feb 14Does Lupin (NSE:LUPIN) Have A Healthy Balance Sheet?
Feb 08We Ran A Stock Scan For Earnings Growth And Lupin (NSE:LUPIN) Passed With Ease
Jan 03Lupin Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Nov 10Shareholder Returns
| LUPIN | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 2.8% | 1.4% | 1.5% |
| 1Y | -10.2% | -7.2% | -4.7% |
Return vs Industry: LUPIN underperformed the Indian Pharmaceuticals industry which returned -7.2% over the past year.
Return vs Market: LUPIN underperformed the Indian Market which returned -4.7% over the past year.
Price Volatility
| LUPIN volatility | |
|---|---|
| LUPIN Average Weekly Movement | 3.4% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 8.3% |
| 10% least volatile stocks in IN Market | 3.2% |
Stable Share Price: LUPIN has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: LUPIN's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 24,006 | Vinita Gupta | www.lupin.com |
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs).
Lupin Limited Fundamentals Summary
| LUPIN fundamental statistics | |
|---|---|
| Market cap | ₹900.73b |
| Earnings (TTM) | ₹36.99b |
| Revenue (TTM) | ₹233.76b |
Is LUPIN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LUPIN income statement (TTM) | |
|---|---|
| Revenue | ₹233.76b |
| Cost of Revenue | ₹74.08b |
| Gross Profit | ₹159.68b |
| Other Expenses | ₹122.68b |
| Earnings | ₹36.99b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 80.99 |
| Gross Margin | 68.31% |
| Net Profit Margin | 15.83% |
| Debt/Equity Ratio | 31.5% |
How did LUPIN perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/04 18:41 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lupin Limited is covered by 78 analysts. 36 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Prashant Nair | Ambit Capital |
| Nitin Bhasin | Ambit Capital |
| Ashwin Mehta | Ambit Capital |